Loading...
•
Sep 30, 2020
Establishment Labs Q3 2020 Earnings Report
Establishment Labs' financial performance remained stable compared to the previous year, with a focus on expense reduction and strategic portfolio expansion.
Key Takeaways
Establishment Labs reported third-quarter revenue of $22.8 million, comparable to the same period in 2019. The company reduced operating expenses by 23% and maintained a strong cash balance of $81.4 million. Full-year revenue guidance is projected to be $80 to $82 million.
Worldwide sales reached $22.8 million, aligning with pre-announced expectations.
Full-year 2020 revenue is anticipated to be in the range of $80 to $82 million.
Operating expenses decreased by 23% compared to the third quarter of 2019.
Cash reserves remained strong at $81.4 million as of September 30.
Forward Guidance
Establishment Labs anticipates continued market share gains through expansion in breast reconstruction and development of new product categories, supporting growth in the coming years while planning entry into the U.S. and China.
Positive Outlook
- Expansion in breast reconstruction market.
- Development of new product categories like minimally invasive augmentation.
- Continued market share gains.
- Entry into the U.S. market planned.
- Entry into the China market planned.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...